<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01181089</url>
  </required_header>
  <id_info>
    <org_study_id>104MS101</org_study_id>
    <nct_id>NCT01181089</nct_id>
  </id_info>
  <brief_title>Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF)and Safety in Subjects With Secondary Progressive Multiple Sclerosis (SPMS)</brief_title>
  <official_title>A Multicenter, Randomized, Blinded, Placebo-Controlled, Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF) and Safety in Subjects With Secondary Progressive Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized, multicenter, dose escalation study to determine subject
      safety, pharmacokinetic, and pharmacodynamic responses in patients with SPMS
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, randomized, placebo-controlled, blinded, dose escalation study
      of 3 to 4 cohorts with defined number of patients per cohort receiving active drug or placebo
      for a period of 4 months followed by safety monitoring for an additional 4 months after the
      last dose
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>September 2010</start_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure: Change in cerebrospinal fluid levels of secondary lymphoid organs chemokines from baseline with baminercept relative to placebo</measure>
    <time_frame>after 4 months of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects experiencing Serious Adverse Event (SAE) and Adverse Event (AE) with baminercept relative to placebo</measure>
    <time_frame>8 months (4 months on drug, 4 months post-drug)</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Secondary Progressive Multiple Sclerosis</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Baminercept</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A diagnosis of Secondary Progressive Multiple Sclerosis

          -  Aged 18 to 57 years old, at the time of informed consent

        Exclusion Criteria:

          -  History of clinically important (as determined by the investigator) cardiac,
             endocrinologic, pulmonary, neurologic, immune, psychiatric, hepatic, renal or
             hematologic insufficiency or any other major disease other than MS ( Multiple
             Sclerosis)

          -  Inability in the opinion of the Investigator to comply with study requirements

          -  Other protocol-defined criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>57 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Canada</country>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2010</study_first_submitted>
  <study_first_submitted_qc>August 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2010</study_first_posted>
  <last_update_submitted>September 12, 2013</last_update_submitted>
  <last_update_submitted_qc>September 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Multiple Sclerosis, Chronic Progressive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

